NLS Pharmaceutics CEO Letter to Shareholders Filed
Ticker: NCEL · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, shareholder-communication
Related Tickers: NLS
TL;DR
NLS Pharma CEO dropped a letter to shareholders, check it out.
AI Summary
On December 11, 2024, NLS Pharmaceutics Ltd. filed a Form 6-K to report the issuance of a press release. This press release, titled "NLS Pharmaceutics CEO Issues Letter to Shareholders," contains a letter from the CEO to the company's shareholders. The filing itself does not contain detailed financial information but serves as notification of the press release.
Why It Matters
This filing indicates that NLS Pharmaceutics' CEO is communicating directly with shareholders, which could contain important updates on company strategy, performance, or future outlook.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a press release and does not contain new financial data or significant operational changes that would immediately impact risk.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- December 11, 2024 (date) — Filing date and press release date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report the issuance of a press release by NLS Pharmaceutics Ltd. titled 'NLS Pharmaceutics CEO Issues Letter to Shareholders'.
When was the press release issued and filed?
The press release was issued and the 6-K filing was made on December 11, 2024.
What is the title of the press release being furnished?
The title of the press release is 'NLS Pharmaceutics CEO Issues Letter to Shareholders'.
Does this filing contain detailed financial results for NLS Pharmaceutics Ltd.?
No, this filing is a Report of Foreign Private Issuer (Form 6-K) and primarily serves to furnish a press release; it does not contain detailed financial results itself.
Where is NLS Pharmaceutics Ltd. headquartered?
NLS Pharmaceutics Ltd. is headquartered in Zurich, Switzerland, with its business address listed as The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 195 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-12-11 08:30:25
Filing Documents
- ea0222021-6k_nlspharma.htm (6-K) — 10KB
- ea022202101ex99-1_nlspharma.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-107656.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 11, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2